TRIB (Trinity Biotech) EPS without NRI: $-1.55 (TTM As of Dec. 2025)


TRIB Trinity Biotech PLC TRIB
28 GF Score
Price $0.37
GF Value $0.74
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Trinity Biotech EPS without NRI?

Trinity Biotech TRIB +6.30% 28 EPS without NRI is $-1.55 as of Dec. 2025. GuruFocus rates TRIB with a GF Score™ of 28/100 and a GF Value™ of $0.74 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 665 Medical Devices & Instruments companies, Trinity Biotech ranks better than 74.74% on this metric.

Trinity Biotech's earnings per share without non-recurring items for the six months ended in Dec. 2025 was $-0.83. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.55.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 27.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Trinity Biotech's EPS without NRI or its related term are showing as below:

TRIB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57.8   Med: -8   Max: 43.4
Current: 27

During the past 13 years, Trinity Biotech's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 43.40% per year. The lowest was -57.80% per year. And the median was -8.00% per year.

TRIB's 3-Year EPS without NRI Growth Rate is ranked better than
74.74% of 665 companies
in the Medical Devices & Instruments industry
Industry Median: 8.1 vs TRIB: 27.00

Trinity Biotech's EPS (Diluted) for the six months ended in Dec. 2025 was $-1.20. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.00.

Trinity Biotech's EPS (Basic) for the six months ended in Dec. 2025 was $-1.20. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.00.


Trinity Biotech  (NAS:TRIB) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Trinity Biotech EPS without NRI Related Terms


Trinity Biotech EPS without NRI Historical Data

* Premium members only.

The historical data trend for Trinity Biotech's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trinity Biotech EPS without NRI Chart

Trinity Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 -3.97 -2.65 -1.83 -1.55

Trinity Biotech Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.71 -0.68 -1.15 -0.72 -0.83

TRIB vs AIDX, NVNO, STME: EPS without NRI Comparison

For the Medical Devices subindustry, Trinity Biotech's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trinity Biotech PE Ratio without NRI vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's PE Ratio without NRI falls into.


TRIB
28GF Score
Trinity Biotech PLC TRIB
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Trinity Biotech EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-1.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-1.55 mean?
Trinity Biotech (TRIB) has a EPS without NRI of $-1.55 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Trinity Biotech and its competitors. According to the industry distribution chart, Trinity Biotech ranks #168 out of 665 companies in the Medical Devices & Instruments industry, placing it in the top 25.3%.
Is Trinity Biotech's EPS without NRI too high?
Trinity Biotech's current EPS without NRI is $-1.55. Based on the distribution chart, Trinity Biotech ranks #168 out of 665 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Trinity Biotech has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's EPS without NRI compare to AIDX and NVNO?
According to the Medical Devices & Instruments industry distribution chart, Trinity Biotech ranks #168 out of 665 companies for EPS without NRI. This puts Trinity Biotech in the upper half of its industry. The industry median EPS without NRI is 8.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.10, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Trinity Biotech and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trinity Biotech's current EPS without NRI is $-1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $0.74, compared to a current price of $0.37 — trading 50.1% below its estimated fair value. The current EPS without NRI is $-1.55. Trinity Biotech's overall GF Score™ is 28/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current EPS without NRI is $-1.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Trinity Biotech (TRIB) Overvalued in 2026?

Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued. The current stock price of $0.37 is trading 50.1% below its estimated GF Value™ of $0.74. GuruFocus considers Trinity Biotech to be Possible Value Trap.

Key valuation signals for TRIB:

  • EPS without NRI: $-1.55
  • GF Value™: $0.74 vs. price of $0.37 (50.1% below fair value)
  • GF Score™: 28/100 with 7 warning signs

No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Trinity Biotech Business Description

Address IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
28GF Score

Get the complete analysis for TRIB

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.37
Price
$0.74
GF Value